JP2023526024A5 - - Google Patents
Info
- Publication number
- JP2023526024A5 JP2023526024A5 JP2022568632A JP2022568632A JP2023526024A5 JP 2023526024 A5 JP2023526024 A5 JP 2023526024A5 JP 2022568632 A JP2022568632 A JP 2022568632A JP 2022568632 A JP2022568632 A JP 2022568632A JP 2023526024 A5 JP2023526024 A5 JP 2023526024A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022860P | 2020-05-11 | 2020-05-11 | |
| US63/022,860 | 2020-05-11 | ||
| PCT/US2021/031616 WO2021231319A1 (en) | 2020-05-11 | 2021-05-10 | Il-2 fusion polypeptide compositions and methods of making and using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526024A JP2023526024A (ja) | 2023-06-20 |
| JP2023526024A5 true JP2023526024A5 (https=) | 2024-05-17 |
| JPWO2021231319A5 JPWO2021231319A5 (https=) | 2024-05-17 |
Family
ID=78524880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568632A Pending JP2023526024A (ja) | 2020-05-11 | 2021-05-10 | Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395325A1 (https=) |
| EP (1) | EP4149514A4 (https=) |
| JP (1) | JP2023526024A (https=) |
| KR (1) | KR20230008759A (https=) |
| CN (1) | CN115867307A (https=) |
| AU (1) | AU2021269585A1 (https=) |
| BR (1) | BR112022022869A2 (https=) |
| CA (1) | CA3172874A1 (https=) |
| IL (1) | IL298064A (https=) |
| MX (1) | MX2022014163A (https=) |
| TW (1) | TW202207971A (https=) |
| WO (1) | WO2021231319A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61391B1 (sr) * | 2012-06-08 | 2021-02-26 | Alkermes Pharma Ireland Ltd | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti |
| EA202092926A3 (ru) * | 2014-03-24 | 2021-10-29 | Биовератив Терапьютикс Инк. | Лиофилизированные составы, содержащие фактор ix |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| MX2019013142A (es) * | 2017-05-05 | 2019-12-16 | Amgen Inc | Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion. |
| UA125971C2 (uk) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування |
| MX2022004577A (es) * | 2019-10-18 | 2022-05-10 | Alkermes Pharma Ireland Ltd | Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune. |
-
2021
- 2021-05-10 MX MX2022014163A patent/MX2022014163A/es unknown
- 2021-05-10 BR BR112022022869A patent/BR112022022869A2/pt unknown
- 2021-05-10 KR KR1020227041366A patent/KR20230008759A/ko active Pending
- 2021-05-10 CN CN202180040284.5A patent/CN115867307A/zh active Pending
- 2021-05-10 AU AU2021269585A patent/AU2021269585A1/en not_active Abandoned
- 2021-05-10 CA CA3172874A patent/CA3172874A1/en active Pending
- 2021-05-10 US US17/315,974 patent/US20210395325A1/en not_active Abandoned
- 2021-05-10 EP EP21804274.5A patent/EP4149514A4/en active Pending
- 2021-05-10 JP JP2022568632A patent/JP2023526024A/ja active Pending
- 2021-05-10 IL IL298064A patent/IL298064A/en unknown
- 2021-05-10 WO PCT/US2021/031616 patent/WO2021231319A1/en not_active Ceased
- 2021-05-11 TW TW110116904A patent/TW202207971A/zh unknown